Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

The summary for the Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed): Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The goal is to create a network of laboratories and canine clinical trial sites. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. Priority attributes include: combinations of immunotherapy/TME-modulating therapy with radiation therapy or other therapies (e.g., targeted therapies, chemotherapies or other immunotherapies); adoptive immune cell therapies such as CAR T-cell therapies or NK cell therapies; studies including longitudinal biopsy; and studies including tumor DNA sequencing and transcriptomics in pet dogs treated with immunotherapeutic agents. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate data generated. A companion funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites (see U24 award supported under companion RFA-CA-21-051).

Federal Grant Title:	Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-21-050
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.393, 93.394, 93.395
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 27th, 2021
Original Application Deadline:	September 27th, 2021
Posted Date:	July 27th, 2021
Creation Date:	July 27th, 2021
Archive Date:	November 2nd, 2021
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	July 27th, 2021

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-050.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional); • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required); • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...; • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...; • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...; • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...; • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required); • NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional); • NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)